KRAS and cancer: In mesenchymal-like cell lines, we identified a clear synergistic effect when combining KRAS G12C inhibitors and pemigatinib suggesting that FGFR activation is a key survival pathway for mesenchymal-like cancer cells treated with KRAS G12C inhibitors.